【佳學(xué)基因檢測(cè)】用于乳腺癌治療的基于透明質(zhì)酸的納米藥物遞送系統(tǒng)：賊新進(jìn)展

腫瘤基因檢測(cè)權(quán)威機(jī)構(gòu)重要性

挖掘基因檢測(cè)人員學(xué)科學(xué)習(xí)手冊(cè)聽到《Front Bioeng Biotechnol》在.?2022 Aug 24;10:990145.發(fā)表了一篇題目為《用于乳腺癌治療的基于透明質(zhì)酸的納米藥物遞送系統(tǒng)：賊新進(jìn)展》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Yufeng Jia,?Siwen Chen,?Chenyu Wang,?Tao Sun,?Liqun Yang?等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究?jī)?nèi)容關(guān)鍵詞：

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

乳腺癌（BC）是全球女性賊常見的惡性腫瘤，對(duì)藥物的高耐藥性和轉(zhuǎn)移率是乳腺癌患者死亡的主要原因。將抗癌藥物正確釋放到腫瘤部位，可以提高療效，減少對(duì)身體的副作用。天然聚合物作為治療乳腺癌的藥物載體引起了廣泛的興趣。透明質(zhì)酸（HA）是一種天然多糖，具有優(yōu)異的生物相容性、生物降解性和非免疫原性，是細(xì)胞外基質(zhì)的重要組成部分。 HA 的 CD44 受體在乳腺癌細(xì)胞中過度表達(dá)，可靶向乳腺腫瘤。因此，許多研究人員開發(fā)了基于 HA 的 CD44 受體腫瘤靶向特性的納米藥物遞送系統(tǒng) (NDDS)。本綜述探討了近年來HA在乳腺癌NDDS中的應(yīng)用。根據(jù) NDDS 的結(jié)構(gòu)組成，它們分為 HA NDDS、Modified HA NDDS 和 HA 混合 NDDS。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

Breast cancer (BC) is the most common malignancy among females worldwide, and high resistance to drugs and metastasis rates are the leading causes of death in BC patients. Releasing anti-cancer drugs precisely to the tumor site can improve the efficacy and reduce the side effects on the body. Natural polymers are attracting extensive interest as drug carriers in treating breast cancer. Hyaluronic acid (HA) is a natural polysaccharide with excellent biocompatibility, biodegradability, and non-immunogenicity and is a significant component of the extracellular matrix. The CD44 receptor of HA is overexpressed in breast cancer cells and can be targeted to breast tumors. Therefore, many researchers have developed nano drug delivery systems (NDDS) based on the CD44 receptor tumor-targeting properties of HA. This review examines the application of HA in NDDSs for breast cancer in recent years. Based on the structural composition of NDDSs, they are divided into HA NDDSs, Modified HA NDDSs, and HA hybrid NDDSs.